| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1086972 | Le Pharmacien Hospitalier et Clinicien | 2012 | 9 Pages |
Abstract
The pharmaceutical compounding of nominative syringes of toxin in CIVAS, through its economic and security aspect, joins completely within the framework of the requirements of the French Contract for Good Use (CGU). It allows the neurologist to save time, thus contributing to the quality of care dispensed to the patient.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmacology, Toxicology and Pharmaceutics (General)
Authors
S. Roche, K. Civiletti, O. Brocque, D. Gayraud, N. Mérité, M.-M. Chaudoreille,